April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Anti-VEGF Anti-Fibrosis - A Comparison of Ranibizumab and Bevacizumab in vitro
Author Affiliations & Notes
  • S. K. Vasudevan
    Ophthalmology, MARA University of Technology, Malaysia, Shah Alam, Malaysia
    Center for Eye Research Australia, University of Melbourne, Australia
  • Footnotes
    Commercial Relationships  S.K. Vasudevan, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 466. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. K. Vasudevan; Anti-VEGF Anti-Fibrosis - A Comparison of Ranibizumab and Bevacizumab in vitro. Invest. Ophthalmol. Vis. Sci. 2009;50(13):466.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Anti-VEGF antibodies, ranibizumab and bevacizumab are being used to inhibit conjunctival fibrosis post trabeculectomy. Their relative toxicity on Tenon’s fibroblasts is not known. This study compared the effects of ranibizumab and bevacizumab on human Tenon’s Fibroblasts (HTF) viability in-vitro.

Methods: : Primary human Tenon’s fibroblasts were treated with ranibizumab and bevacizumab for 72 hours at a 50th, a 10th, a half and at the full human intravitreal dose. Fibroblast number and viability were assessed using the MTT (3-(4, 5-Dimethylthiazol-2-Yl)-2, 5-Diphenyltetrazolium Bromide) colorimetric assay.

Results: : Ranibizumab induced a greater dose dependent reduction in HTF cell numbers as compared to bevacizumab. At a 50th of a commonly used human intravitreal dose, ranibizumab showed a 19% (SD +/- 9%) reduction in HTF number as compared to a 1% (SD +/-4%) reduction in HTF by bevacizumab at a similar dilution. At a commonly used human intravitreal dose, ranibizumab led to a 38% (SD +/-5%) reduction in fibroblast numbers as compared to a 15% (SD +/- 9%) reduction by bevazicumab at 72 hours.

Keywords: wound healing • clinical laboratory testing • apoptosis/cell death 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.